Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 9/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 9/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 9/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 5/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.83 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.77 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.77 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22204241 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22440905 | 0.90 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22440906 | 0.90 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL19329781 | 0.90 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22204266 | 0.89 | PIK3CG (0.87) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22204264 | 0.89 | PIK3CG (0.87) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL24624676 | 0.89 | PIK3CG (0.82) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22204249 | 0.88 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22204247 | 0.88 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL29444678 | 0.88 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| CN-115677692-A | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11542262-B2 | Phosphatidylinositol 3-kinase inhibitors | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| CN-114025756-B | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20220220113-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220213096-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO LTD (CN) | 2022-07-07 | — | — | US | disclosed |
| EP-3952870-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. (CN) | 2022-02-16 | — | — | EP | disclosed |
| CN-114025756-A | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-3426652-B1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| CN-108779110-B | Novel inhibitors of phosphatidylinositol 3-kinase gamma | 阿斯利康(瑞典)有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20210246130-A1 | DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | ASTRAZENECA AB (SE) | 2021-08-12 | — | — | US | disclosed |
| US-10961236-B2 | (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2021-02-18 | — | — | US | disclosed |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | ASTRAZENECA AB (SE) | 2020-12-08 | — | — | US | disclosed |
| WO-2020210379-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
| US-20200308164-A1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | ASTRAZENECA AB (SE) | 2020-10-01 | — | — | US | disclosed |
| US-20200299289-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2020-09-24 | — | — | US | disclosed |
| EP-3515910-B1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | ASTRAZENECA AB (SE) | 2020-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308164-A1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | PIK3CD, PIK3CG, PDPK1 | PIK3CG 2/4885PIK3CD 1/4885PIK3R1 44/4885 |
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | PIK3CD, PIK3CG, PIK3CA | PIK3CG 2/4885PIK3CD 1/4885PIK3R1 18/4885 |
| US-11542262-B2 | Phosphatidylinositol 3-kinase inhibitors | PI4KB, PI4KA, PIK3CD | PIK3CG 8/4885PIK3CD 3/4885PIK3R1 19/4885 |
| US-10961236-B2 | (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor | PIK3CD, PIK3CB, PIK3CA | PIK3CG 4/4885PIK3CD 1/4885PIK3R1 29/4885 |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | PIK3CD, PIK3CG, PIK3CA | PIK3CG 2/4885PIK3CD 1/4885PIK3R1 18/4885 |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PIK3CG 8/4885PIK3CD 3/4885PIK3R1 19/4885 |
| US-20220220113-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PIK3CG 8/4885PIK3CD 3/4885PIK3R1 19/4885 |
| US-20200299289-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | PI4KA, PIK3CD, PI4KB | PIK3CG 4/4885PIK3CD 2/4885PIK3R1 50/4885 |
| US-20210246130-A1 | DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | PIK3CD, PIK3CG, PRKCG | PIK3CG 2/4885PIK3CD 1/4885PIK3R1 37/4885 |
| US-20220213096-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PIK3CG 8/4885PIK3CD 3/4885PIK3R1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.